TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population by Loebinger, M R et al.
TRAIL-expressing mesenchymal stem cells kill the putative cancer
stem cell population
MR Loebinger
1, EK Sage
1, D Davies
2 and SM Janes*,1
1Centre For Respiratory Research, Rayne Institute, University College London, 5 University Street, London WC1E 6JJ, UK;
2Flow Cytometry Laboratory,
Cancer Research UK, London Research Institute, 44 Lincoln’s Inn Fields, London WC2A 3PX, UK
BACKGROUND: Tumours contain stem-like, side population (SP) cells, which have increased tumorigenic potential, resistance to
traditional therapies and may be responsible for treatment failures and relapse in patients.
METHODS: Mesenchymal stem cells (MSCs) were engineered to express the apoptotic ligand, TNF-related apoptosis-inducing ligand
(TRAIL). Squamous (H357) and lung (A549) cancer cell lines were sorted into side and non-side populations (non-SP) by Hoechst
flow cytometry. The survival and growth of both SP and non-SP cancer populations, in conjunction with TRAIL-expressing MSCs and
mitoxantrone chemotherapy, were assessed by flow cytometry and colony forming ability.
RESULTS: Mesenchymal stem cells expressing TRAIL migrate to tumours and reduce the growth of primary cancers and metastases.
This report demonstrates that these cells cause apoptosis, death and reduced colony formation of the SP of squamous and
adenocarcinoma lung cancer cells and are synergistic when combined with traditional chemotherapy in apoptosis induction.
CONCLUSIONS: The sensitivity of putative cancer stem cells to TRAIL-expressing MSCs, suggests their possible role in the prevention
of cancer relapse.
British Journal of Cancer (2010) 103, 1692–1697. doi:10.1038/sj.bjc.6605952 www.bjcancer.com
Published online 9 November 2010
& 2010 Cancer Research UK
Keywords: mesenchymal stem cell; cancer stem cell; side population; lung cancer; TRAIL; apoptosis
                                             
Cancers are composed of a heterogeneous mix of cells with
varying differentiation, proliferation and tumorigenic properties
(Heppner, 1984; Loebinger et al, 2008b). Indeed, in vivo studies
have demonstrated that within a cancer population, only a small
percentage of potential ‘cancer stem cells’ are able to initiate
tumour development (Lapidot et al, 1994; Al-Hajj et al, 2003;
Loebinger et al, 2008b) (Visvader and Lindeman, 2008). Conven-
tional cancer treatments may eradicate the tumour bulk but spare
these cells, which may explain why an initial tumour regression
does not necessarily translate to an improved patient survival in
many clinical trials for advanced cancers (Wicha et al, 2006).
The identification and destruction of these stem cells may
therefore improve cancer treatment responses. Cell surface
markers have been used in some cancers to produce a population
of cells enriched with stem cell properties, for example, CD133 in
the identification of human glioma (Singh et al, 2004) and colon
cancer (Ricci-Vitiani et al, 2007) stem cells. However these
markers appear specific to particular tumours and no marker
has identified cancer stem cells across tumour types. Normal stem
cell characteristics are often utilised to identify this population.
This includes the ability to efflux nuclear dyes such as Hoechst
33342, which binds to DNA. The efflux of Hoechst is due to
ABC transporters, in particular ABCG2/BCRP1 (Zhou et al, 2001).
These Hoechst-effluxing cells were originally described in the
bone marrow and termed ‘side population’ (SP) owing to
their appearance on flow cytometry plots (Goodell et al, 1996).
They have since been shown in a variety of normal tissues,
wherein they possess stem-like properties (Wu and Alman, 2008).
They have also been identified in many cancers, including lung
(Ho et al, 2007; Sung et al, 2008), breast (Engelmann et al, 2008),
oesophageal (Huang et al, 2009), hepatocellular (Kamohara et al,
2008), glioma (Harris et al, 2008), renal (Addla et al, 2008) and
squamous (Loebinger et al, 2008b) cancer cell lines, in addition to
primary cancer cells (Barrett et al, 1995; Hirschmann-Jax et al,
2004; Szotek et al, 2006; Wu et al, 2007).
We, and others, have previously demonstrated that this
Hoechst-effluxing, SP of cells within cancers have many stem-like
properties, including the ability to re-populate both the SP and
non-Hoechst efflux ability non-side populations (non-SP) cell
compartments, an increased ability to form colonies and generate
complex spheroids in three-dimensional culture, a high telomerase
activity and increased quiescence (Kondo et al, 2004; Ho et al,
2007; Addla et al, 2008; Loebinger et al, 2008b; Zhang et al, 2009).
They have also been shown to express a number of stem-like genes
(including OCT-4, SOX-2 and BMI-1) (Huang et al, 2009; Zhang
et al, 2009), ABC transporter genes (including ABCG2) (Loebinger
et al, 2008b; Huang et al, 2009; Zhang et al, 2009), and genes
involved in the Wnt (Haraguchi et al, 2006; Addla et al, 2008;
Huang et al, 2009), Notch (Addla et al, 2008; Huang et al, 2009),
PI3K/Akt pathways and cell cycle regulation (Zhou et al, 2007).
Side population cells derived from both primary tumours (Wu
et al, 2007) and cancer cell lines (Chiba et al, 2006; Ho et al, 2007;
Loebinger et al, 2008b) also have an increased ability to initiate
tumours compared with the majority of the tumour cells, when
xenografted into immunodeficient mice. Furthermore, we, and
others, have demonstrated that the SP cells are able to escape death
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sby many chemotherapeutic agents, owing in part to their relative
quiescence, in addition to increased ABC transporter expression
which leads to the efflux of lipophilic chemotherapy agents such as
mitoxantrone (Hirschmann-Jax et al, 2004; Loebinger et al, 2008b).
This combination of resistance and tumour initiation makes it
likely that these SP cells are central to tumour growth and
recurrence, and stresses the importance of targeting these cells
with future cancer therapies.
Mesenchymal stem cells (MSCs) have been used as delivery
vehicles for targeted, antitumour therapies (Studeny et al, 2002;
Loebinger et al, 2008a,c). These cells are derived from the adult
bone marrow and have the ability to specifically home towards
tumours throughout the body. In addition, they are immuno-
privileged, enabling their use without rejection or immuno-
suppressive pre-conditioning. We, and others, have engineered
MSCs to express TNF-related apoptosis-inducing ligand (TRAIL)
(Loebinger et al, 2009; Szegezdi et al, 2009; Grisendi et al, 2010).
TRAIL is a protein which causes apoptosis and death of cancer
cells, without harming normal cells, by binding to specific TRAIL
receptors and leading to activation of the extrinsic apoptosis
pathway (Wiley et al, 1995). In vivo studies have demonstrated that
these cells are able to target multiple tumours and reduce primary
and metastatic disease (Loebinger et al, 2009; Grisendi et al, 2010).
The ability of this therapy to target and kill the putative cancer
stem cells has not been determined. We hypothesised that MSC-
delivered TRAIL therapy would target SP and non-SP cells equally.
MATERIALS AND METHODS
Tissue culture
Human adult MSCs were provided through the Tulane Centre for
Gene Therapy, MSC cell distribution centre (New Orleans, LA,
USA) and cultured in aMEM with 4mML -Glutamine, 50Uml
 1
penicillin and 50mgml
 1 streptomycin, and 16% (v/v) fetal bovine
serum. H357 cells were provided by Cancer Research UK, and
cultured in a 1:3 mix of Hams F12 medium and Dulbecco’s
modified Eagle’s medium (Janes and Watt, 2004). In addition to
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Figure 1 Squamous cancer and adenocarcinoma cancer cell lines
contain a SP. (A, B) Representative flow cytometry plots demonstrating
that H357 (A) and A549 cell lines (B) but not the MDAMB231 breast
cancer cell line (C) contain a SP of cells that stain poorly with Hoechst.
Cells were labelled with 7.5mgml
 1 Hoechst 33342 for 45min. This
population disappears with the ABC transporter inhibitor, reserpine
(5mM). The gates show the cells defined as SP and non-SP for the
experiments.
***
T
R
A
I
L
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
p
g
 
m
l
–
1
)
Early apoptotic
P
e
r
c
e
n
t
a
g
e
 
o
f
 
c
e
l
l
s
rT10 rT50 rT100 rT200 MSC ND MSC dox
60
50
40
30
20
10
0
Late apoptotic
A549
MSCFLT no dox MSCFLT dox
***
***
800
700
600
500
400
300
200
100
0
Figure 2 Mesenchymal stem cell TRAIL expression and killing effect
compared with recombinant TRAIL. (A) ELISA demonstrating level of
TRAIL produced in TRAIL transduced MSCs with and without addition
of 10mgml
 1 doxycycline for 48h. (B) Bar chart demonstrating the
percentage of apoptosis in A549 cells with increasing levels of recombinant
TRAIL (rT) 10–200ngml
 1 and doxycycline-induced TRAIL expression.
Experiments were performed in triplicate. ***Po0.001.
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sfetal bovine serum, L-Glutamine and antibiotics, this medium was
supplemented with 10
 10M cholera enterotoxin (ICN Pharmaceu-
ticals Ltd., Oxon, UK), 0.5gml
 1 hydrocortisone, 10ngml
 1
epidermal growth factor and 5mgml
 1 insulin (Janes et al, 2004).
A549 and MDAMB231 cells were provided by Cancer Research UK
and cultured in Dulbecco’s modified Eagle’s medium.
Production of TRAIL-transduced MSCs
Mesenchymal stem cells were transduced with membrane-bound
TRAIL and green fluorescent protein, under the control of a
Tetracycline-on promoter, using a lentivirus, as previously
described (Loebinger et al, 2009). The transduced MSCs (MSCFLT)
expressed TRAIL and green fluorescent protein only on addition of
10mgml
 1 doxycycline (Loebinger et al, 2009). Human TRAIL
expression was verified by ELISA (R&D Systems, Abingdon, UK)
as per manufacturer’s instructions.
SP identification and sorting
To identify the SP, previously described protocols were followed
(Loebinger et al, 2008b). Cancer cells were harvested at full
confluence, re-suspended at 1 10
6 cellsml
 1 in medium and
labelled with 2.5, 5, or 7.5mgml
 1 Hoechst 33342 for 45, 60,
or 90min at 371C to determine the required incubation time.
Dead cells were excluded with propidium iodide labelling. The
multidrug transporter inhibitor, reserpine (5mM) was used to
demonstrate specificity of the SP. Analysis was performed on an
LSR2 machine (Becton Dickenson, Oxford, UK). The optimal
staining conditions were 5mgml
 1 Hoechst 33342 for 45min and
7.5mgml
 1 Hoechst 33342 for 60min for the H357 and A549 cells,
respectively (Loebinger et al, 2008b). The SP and non-SP
population (1 10
6 of each cell type) were sorted according to
the gates in Figure 1 using a MoFlo High-Performance Cell Sorter
(Dako, Glostrup, Denmark).
Co-culture
Cancer cells were stained with the fluorescent dye DiI (according
to the manufacturer’s instructions, Invitrogen, Paisley, UK), before
any cell sorting, and plated with MSCFLT cells (passage seven after
transduction) in a 6-well plate (5 10
4 of each cell type). The
following day doxycycline was added and left for 48h. The early
and late apoptosis of the cells in co-culture was assessed by
Annexin V-based flow cytometry with DAPI or propidium
iodide. Annexin V
 /DAPI
  (or PI
 ) cells were judged to be
viable, Annexin V
þ/DAPI
  cells were considered to be undergoing
early apoptosis, and Annexin V
þ/DAPI
þ cells were considered
late apoptotic (Loebinger et al, 2009). In subsequent assays, the
cancer cells were pre-treated with 10ngml
 1 of mitoxantrone
before the addition of 5 10
4 MSCs (passage 9 and 10) or
apoptosis induced by MSCFLT was compared with recombinant
TRAIL (using manufacturer’s guideline doses) for 48h.
Colony formation
In all, 200 DiI-stained and then freshly sorted, SP or non-SP
H357 cells were added to a 6-well plate. The following day,
5 10
4 MSCFLT cells, treated with mitomycin C to prevent
their continued proliferation were added to the plates and the
TRAIL transgene either activated or not with doxycycline. After
14 days of co-culture, colonies were washed, fixed using 3% PFA,
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Figure 3 TNF-related apoptosis-inducing ligand-expressing MSCs lead to apoptosis of H357 and A549 SP and non-SP cells. Freshly sorted DiI-labelled
A549 (A–C) or H357 (D) SP and non-SP cells were co-cultured with MSCFLT cells with (dox) or without (ND) doxycycline for 48h. (A, B)
Representative flow cytometry plots demonstrating the percentage of early and late apoptotic non-SP (A) and SP (B) A549 cells. (C, D) Bar charts
representing triplicate experiments demonstrating the increase in early and late apoptosis with doxycycline-induced TRAIL expression in both the SP and
non-SP subgroups of A549 (C) and H357 (D) cells. ***Po0.001.
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sand stained with Rhodanile Blue overnight. Colonies were
counted using an Olympus CK2 inverted phase-contrast light
microscope (Olympus, Essex, UK). A large colony was defined as
greater than 32 cells per colony and abortive colonies were defined
as colonies that contained fewer than 32 cells (Loebinger et al,
2008b).
RESULTS
Squamous and lung cancer cell lines contain an ABC
transporter SP
Many cancer cell lines and primary cells contain a SP. In order to
identify whether squamous cell, lung and breast carcinomas
contain a similar subpopulation of drug-resistant SP cells,
confluent H357 (squamous), A549 (lung) and MDAMB231
(breast) cancer cell lines were incubated with Hoechst 33342 dye
and analysed by flow cytometry. A characteristic SP fraction
was detected in the H357 and A549 cell lines, but not in the
MDAMB231 cells, which is consistent with a previous report
(Engelmann et al, 2008). The squamous and lung SPs were both
reserpine sensitive, indicating their dependence on ABC-type
transporter activity (Figures 1A–C).
The SP cells can be killed by TRAIL-expressing MSCs
TRAIL-expressing MSCs have previously been shown to have the
ability to cause cancer cell death and decrease tumour and
metastasis development in vivo (Loebinger et al, 2009). In these
experiments, the TRAIL lentivirus is conditionally activated with
the addition of doxycycline, and carries green fluorescent protein
to enable the monitoring of gene activation. We initially confirmed
the production of TRAIL after activation of the transgene. MSCFLT
cells were cultured with or without doxycyline for 48h and
cells harvested for protein measurement by ELISA. Doxycyline
treatment led to 660 vs 2.92pgml
 1 (P¼o0.001) without treat-
ment (Figure 2A). In co-culture experiments using H357 cells, we
confirmed sensitivity of unsorted populations of these cells to
doxycycline treated MSCFLT cells and found H357 cells more
sensitive to MSCFLT cells than high doses of recombinant protein
(Figure 2B) as previously seen by our laboratory (Loebinger et al,
2009).
The cancer stem cell hypothesis suggests that their destruction is
crucial for a cancer therapy. Having isolated a population enriched
for possible cancer stem cells (SP) in both squamous and lung
cancer cell lines, their susceptibility to the doxycycline-controlled,
TRAIL-expressing MSC therapy was tested in co-culture experi-
ments. SP and non-SP cells were freshly flow-sorted from
DiI-stained H357 and A549 cells (Figure 1) and immediately
co-cultured with the MSCFLT cells. The death and apoptosis of
the cancer cells in co-culture was assessed by Annexin V flow
cytometry. There was a significant increase in apoptosis of both
the SP and non-SP subgroups of A549 cells with the use of
doxycycline and activation of the TRAIL transgene (SP: 2.7±0.5%
increased to 27.7±1.9%, non-SP: 4.4±1.5% increased to
30.4±1.6%) (Figure 3A–C) and H357 cells (SP: 13.4±1.4%
increased to 68.1±5.5%, non-SP: 16.1±1.4% increased to
60.9±2.5%) (Figure 3D) (both Po0.001, Anova).
The susceptibility of the cancer cell subpopulations to TRAIL-
expressing MSCs was further assessed with colony forming assays.
In all, 200 DiI-stained and then freshly sorted, SP or non-SP H357
cells were added to a 6-well plate. The following day, 5 10
4
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Figure 4 TRAIL-expressing MSCs reduce the clonogenic potential of H357 SP and non-SP cells and produce additional SP cancer cell killing to
mitoxantrone treatment. (A, B) In all, 200 DiI-labelled, SP (A) or non-SP (B) H357 cells were plated for colony forming assays before the addition of
5 10
4 TRAIL-expressing MSCs (MSCFLT). (C) Quantification of large colony numbers from (A, B) demonstrates a reduction in large colonies with
doxycyline (dox)-induced TRAIL expression in both SP and non-SP cells compared with the co-cultures without dox (ND). Furthermore, SP cells produced
more colonies than non-SP cells. (D) Phase-contrast and (E) fluorescent microscopy demonstrate the green fluorescent protein (green) from the
doxycycline (dox)-activated MSCFLTs surrounding the DiI-labelled (red) H357 colonies. (F) SP cells were exposed to mitoxantrone (Mitox) and then
co-cultured with MSCFLT cells. Bar chart represents triplicate flow cytometry experiments and demonstrates a further increase in death and apoptosis of the SP
cells with the addition of doxycycline and activation of MSCFLT TRAIL expression. ***Po0.001, **Po0.01, ns, non-significant. Scale bars represent 25mm.
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sgrowth) were added to the plates and the TRAIL transgene either
activated or not with doxycycline. As expected from previous work
(Loebinger et al, 2008b), colony formation was greater in the SP
subgroup compared with the non-SP cells (60.0±1.7 large colonies
in the SP cells compared with 34.0±7.8 large colonies in the
non-SP cells) (Po0.001, 2-way Anova). Colony formation was
significantly inhibited in both cell subgroups with the doxycycline-
induced activation of the TRAIL transgene of the MSCs (SP:
60±1.7 large colonies reduced to 14.7±4.2 large colonies with
TRAIL expression, non-SP: 34.0±7.8 large colonies reduced to
8.0±1.7 large colonies with TRAIL expression) (both Po0.001,
two-way Anova) (Figure 4A–E).
The addition of TRAIL-expressing MSCs to mitoxantrone
treatment causes further cancer cell killing
The DiI-labelled, SP H357 cells were treated with 10ngml
 1
mitoxantrone for 3 days followed by co-culture with MSCFLT cells.
The Annexin V flow cytometry assay was used to determine the
early and late apoptotic SP cancer cells. There was a significant
increase in apoptotic cells with the addition of doxycycline and
activation of the TRAIL transgene (56.3±10.0% with doxycycline,
compared with 33.9±2.4% without doxycyline) (Po0.01, Anova)
(Figure 4F). This suggests a further cancer killing effect of the
TRAIL-expressing MSCs above and beyond the mitoxantrone
chemotherapy agent. Indeed, when TRAIL was not expressed
with doxycycline, the use of mitoxantrone alone did not
significantly increase the early and late apoptotic cancer cells,
consistent with a degree of mitoxantrone chemoresistance of
the SP cells as discussed above (33.9±2.4% with mitoxantrone
compared with 24.56±4.2% without mitoxantrone) (P40.05,
Anova) (Figure 4F).
DISCUSSION
One feature of the SP, or subgroup of cells enriched for stem
cells, is their resistance to common oncological treatments
(Loebinger et al, 2009). These studies have demonstrated that
this subpopulation has some resistance to chemotherapy agents
such as mitoxantrone. This subgroup of cells has also been
shown to be more capable of tumour initiation in subcutaneous
models (Hirschmann-Jax et al, 2004; Loebinger et al, 2008b).
The combination of increased treatment resistance and ability to
re-populate tumours suggest new treatments should target these
cells effectively. Our co-culture experiments with MSCFLT cells
demonstrate that TRAIL-expressing MSCs are able to kill both SP
and non-SP cells in squamous and adenocarcinoma lung cell lines
with equal efficacy. This suggests that TRAIL-expressing MSCs
could be a useful agent for cancer treatment either alone, or
potentially in combination with other radiotherapy and chemo-
therapy regimens. The benefits of a combination approach were
demonstrated in our study, with an improved SP killing when both
mitoxantrone and TRAIL-expressing MSCs were used. The killing
of H357 cells with activation of MSCFLT cells was higher than
A549 cells (as demonstrated previously (Loebinger et al, 2009))
presumably due to a difference in TRAIL sensitivity.
The potential of using TRAIL to destroy putative cancer
stem cells has been recognised by others. One study demonstrated
TRAIL-induced apoptosis of CD133-positive glioma cells (Saspor-
tas et al, 2009), a second showed radioresistant oesophageal cancer
cells were 10 times more susceptible to TRAIL therapy (Zhang
et al, 2008) and a further study noted an increased sensitivity of
colon cancer SP cells to recombinant TRAIL therapy (Sussman
et al, 2007). However, a paper by Capper et al showed CD133
glioma cells capable of neurosphere formation were completely
resistant to TRAIL. Our study has two novel findings. First, we
demonstrated that the combination of TRAIL with MSCs can target
both SP and non-SP fractions and second, that their combination
with traditional chemotherapies has a synergistic effect. We believe
this lends important further evidence to the development of
this cellular therapy in combination with current chemotherapy
regimes.
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